KOD
NASDAQKodiak Sciences Inc
Price$45.28+0.03 (+0.07%)
01:30 PM07:45 PM
News · 26 weeks29+100%
2025-10-262026-04-19
Mix1490d
- SEC Filings6(43%)
- Insider5(36%)
- Other2(14%)
- Offering1(7%)
Latest news
25 items- SECSEC Form DEFA14A filed by Kodiak Sciences IncDEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form DEF 14A filed by Kodiak Sciences IncDEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)
- INSIDERSEC Form 4 filed by Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form S-8 filed by Kodiak Sciences IncS-8 - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form 10-K filed by Kodiak Sciences Inc10-K - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsPALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."The GLOW2 Phase 3 study delivered strong topline results showing meaningful efficacy, safety and durability of Zenkuda (tarcocimab tedromer) in
- INSIDERSEC Form 4 filed by Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamBuilding on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).Zenkuda also demonstrated superiority to sham with an 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001) and with a ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001).Zenkuda demonstrated strong efficacy independent of concomitant GLP-1 receptor agonist use. In
- INSIDERSEC Form 4 filed by Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERPerlroth Victor decreased direct ownership by 0.59% to 2,095,538 units (SEC Form 5)5 - Kodiak Sciences Inc. (0001468748) (Issuer)
- PRFinal APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothel
- PRKodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferencePALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2026, at 1:30 p.m. Pacific Time. A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event. About Kodiak Sciences Inc. Kodiak Sciences (NASDAQ:KOD) is a precommercial ret
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kodiak Sciences IncSCHEDULE 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
- INSIDERDirector Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- PRKodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional SharesPALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering ex
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form 424B5 filed by Kodiak Sciences Inc424B5 - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Pricing of Upsized Public Offering of Common StockPALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering are expected to be approximately $160 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about December 18, 2025, subject to customary closing con
- SECSEC Form 424B5 filed by Kodiak Sciences Inc424B5 - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Proposed Public Offering of Common StockPALO ALTO, Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public offering of 6,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Kodiak Sciences. The proposed offering is subject t
- SECSEC Form 10-Q filed by Kodiak Sciences Inc10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)